Navigation Links
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Date:4/23/2009

NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a standard review classification by the U.S. Food and Drug Administration (FDA). Therefore, a user fee goal date of December 12, 2009 for a decision by the FDA with respect to the approval of the Company's NDA has been established.

The Company had previously announced the acceptance of the NDA filing for review by the FDA on April 16, 2009. The NDA presents data for Onrigin(TM) as a single agent for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The NDA is based on the results of an international multi-center pivotal Phase II trial of 85 patients sixty years of age or older with de novo poor-risk AML, supplemented by data from 55 patients in a previous Phase II trial in elderly AML. Eighty-six percent of these 140 patients had two or more risk factors that predicted for a poor prognosis.

Alan Kessman, Chief Executive Officer, commented, "Our level of excitement continues to grow as we move forward in the FDA's process of reviewing our NDA. We will continue to work closely with the FDA on the filing with the objective of achieving approval for Onrigin(TM) in its first indication in the United States." He added, "The positive news today is that we can expect to have an FDA decision this year."

About Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(TM)(laromustine) Injection and Triapine(R). The FDA is reviewing a New Drug Applicat
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
4. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
5. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
11. Amylin Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Many people complain about their dependence on eyeglasses. For ... put on glasses to see their clock or make their ... be dissatisfied with their vision even when using their glasses ... driving, especially at night due to glare. They can ... see the TV, sew or cross stitch, or read fine ...
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, 2014 ... a single dose of the hormone oxytocin quickly improved their ... Known as the "love hormone," oxytocin has been shown ... between mothers and their children. In this study, it ... brain that has long been associated with the processing of ...
(Date:7/29/2014)... During his 37 years in dental practice, Dr. Arthur ... a steady stream of college students shadow him in order ... on to dental school and some are now practicing dentistry ... college students find success. , For students interested in applying ... to see a realistic view of what goes on in ...
(Date:7/29/2014)... A unique app that helps headache sufferers to record ... used as part of a Griffith research study. , ... ENHANCE project looks at coping with their triggers and ... Health Institute,s Behaviorial Basis of Health program. , He ... cope with the triggers of their headaches called Learning ...
(Date:7/29/2014)... Palm Beach, Florida (PRWEB) July 29, 2014 ... new scholarship for law students this week. The scholarship will ... of abused children and their families. , Steinger, Iscoe and ... past abuse, and want tomorrow’s attorneys to do the same. ... States each year according to the nonprofit Childhelp ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2
... national study, patients being treated for a rare ... University Hospital// (NSUH) and Long Island Jewish (LIJ) ... compound, coupled with standard chemotherapy treatments, significantly increases ... acute promyelocytic leukemia, or APL, and participated in ...
... the standard breast cancer therapy drug tamoxifen, to another one ... , Publishing their findings in the online version of The ... Institute, UK, and team, stood for changing treatments tracks to ... as it reduced deaths by 17 percent. ,Their ...
... encouragement to shut those eyes//. ,Scientists from the ... results that may make it worthwhile to have an afternoon ... Trichopoulos, lead researcher, looked at sleep patterns in Mediterranean countries ... Incidence or rates of heart diseases are low in ...
... Calcium and vitamin D supplementation, even over a short time ... bone) in female military// recruits, according to a study. ... of Defense, looked at 5,201 female U.S. Navy recruits during ... Great Lakes Naval Station near Chicago, Ill. ,The ...
... currently underway brings hope of dramatic advances in ... The review reveals that new approaches in breast ... and research on breast cancer vaccines may lead ... treating breast cancer patients. These new tools may ...
... Centre is planning to set up a 200-bed super ... centres with an initial investment of Rs.300 million. ... of the hospital, told IANS: "We are going to ... in Bangladesh with an aim to provide quality and ...
Cached Medicine News:Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2Health News:Mid-day Naps Healthy for Your Heart 2Health News:Calcium, Vitamin D Supplements Reduce Stress Fractures in Military Recruits 2Health News:Emerging Research Heralds New Era of Breast Cancer Management 2Health News:Kolkata's Birla Hospital to Foray into Bangladesh 2
(Date:7/29/2014)... Holding Company (Nasdaq: ESRX ) announced 2014 ... of $515.2 million, or $0.67 per diluted share.  Adjusted ... was $1.23 for the second quarter. 1 ... with scale, alignment and innovative solutions to lower costs, manage ... stated George Paz, chairman and chief executive officer.  "We ...
(Date:7/29/2014)... 29, 2014  Sequenom, Inc. (NASDAQ: SQNM ... solutions, today reported total revenues of $39.8 million for ... compared to revenues of $24.5 million for the second ... segment, which was sold on May 30, 2014, has ... its results have been excluded from continuing operations for ...
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, Inc. ... on the Phase 3 clinical development of Revolixys™ Kit ... drug system, today announced that it will hold a ... 12, 2014, at 8:30 a.m. EDT to discuss its ... Interested participants and investors may access the conference ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6
... A OIA MAX test delivers excellent sensitivity ... Strep with a simple, easy-to-use test that ... of performance, speed, and ease-of-use enables you ... overall costs for diagnosing and treating patients ...
... A/B test combines performance equivalence to 14-day viral ... or B with a simple, easy-to-use test with ... has all the same procedural steps as our ... you decrease costs for unnecessary ancillary testing, improve ...
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
Shielding's Flex Back Apron is one of our most popular. Similar to the Velcro Adjustable but with elastic back panels for additional support and comfort....
Medicine Products: